ALEXANDER EGGERMONT, general director of Institut Gustave Roussy since 2010, has had his appointment as head of the institute renewed by the French minister of health for another five years. The institute is one of the largest health centers in Europe dedicated to oncology. The past five years has seen a large investment program at... […]
If Congress passes another year-long, flat-funding resolution, the effect on NIH “would be simply devastating,” Director Francis Collins told a Senate appropriations subcommittee during a hearing Oct. 7.
MD Anderson Cancer Center and Theraclone Sciences launched OncoResponse, an immuno-oncology antibody discovery company.
CT colonography and stool DNA failed to get on the list of preferred tools for screening for colorectal cancer. A draft guideline from the U.S. Preventive Services Task Force released Oct. 6 calls for using one of three strategies: Fecal immunochemical test or high-sensitivity guaiac-based fecal occult blood test every year; Flexible sigmoidoscopy every ten... […]
FDA granted Priority Review for defibrotide for the treatment of patients with hepatic veno-occlusive disease, also known as sinusoidal obstruction syndrome, with evidence of multi-organ dysfunction following hematopoietic stem-cell transplantation.
The European Medicines Agency Committee for Medicinal Products for Human Use delivered two positive opinions, recommending marketing authorization for Kyprolis and Blincyto.
FDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced non-small cell lung cancer whose disease has progressed after other treatments and with tumors that express the protein PD-L1.
RICHARD O'REILLY will step down as chair of pediatrics at Memorial Sloan Kettering Cancer Center, after nearly 30 years. He will serve as chair until a successor is found, according to Physician-in-Chief Jose Baselga.
Congress passed a continuing resolution Sept. 30—averting a shutdown—that will fund the federal government at current levels through Dec. 11.Funding for both NIH and NCI dipped slightly as part of a 0.21 percent cut to all non-defense discretionary agencies.
The U.S. Preventive Services Task Force published a viewpoint in the Journal of the American Medical Association to clarify how their recommendations are linked to the Affordable Care Act coverage mandate—and how they believe clinicians, payers, and the public should interpret their recommendations.
